Clinuvel Pharmaceuticals Limited (FRA:UR9)
Germany
· Delayed Price · Currency is EUR 7.00
+0.23 (3.40%)
At close: Dec 5, 2025
Clinuvel Pharmaceuticals Ratios and Metrics
Market cap in millions EUR. Fiscal year is July - June.
Millions EUR. Fiscal year is Jul - Jun.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 4, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Market Capitalization | 353 | 290 | 479 | 539 | 484 | 959 | Upgrade
|
| Market Cap Growth | -11.66% | -39.41% | -11.00% | 11.37% | -49.58% | 23.36% | Upgrade
|
| Enterprise Value | 225 | 180 | 371 | 454 | 419 | 914 | Upgrade
|
| Last Close Price | 7.00 | 5.73 | 9.24 | 10.84 | 9.70 | 18.94 | Upgrade
|
| PE Ratio | 17.47 | 14.38 | 21.60 | 28.87 | 35.14 | 61.34 | Upgrade
|
| PS Ratio | 6.65 | 5.48 | 8.73 | 11.28 | 11.16 | 31.39 | Upgrade
|
| PB Ratio | 2.62 | 2.16 | 3.79 | 5.37 | 5.84 | 15.36 | Upgrade
|
| P/TBV Ratio | 2.63 | 2.16 | 3.80 | 5.37 | 5.85 | 15.39 | Upgrade
|
| P/FCF Ratio | 15.49 | 12.75 | 24.46 | 24.62 | 18.61 | 82.41 | Upgrade
|
| P/OCF Ratio | 15.38 | 12.66 | 20.77 | 23.93 | 18.40 | 78.75 | Upgrade
|
| EV/Sales Ratio | 4.16 | 3.40 | 6.76 | 9.50 | 9.68 | 29.91 | Upgrade
|
| EV/EBITDA Ratio | 8.43 | 6.94 | 12.09 | 16.71 | 17.68 | 49.73 | Upgrade
|
| EV/EBIT Ratio | 8.64 | 7.05 | 12.28 | 16.86 | 17.89 | 50.60 | Upgrade
|
| EV/FCF Ratio | 9.90 | 7.91 | 18.95 | 20.73 | 16.13 | 78.52 | Upgrade
|
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Debt / EBITDA Ratio | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.04 | Upgrade
|
| Debt / FCF Ratio | 0.01 | 0.01 | 0.03 | 0.03 | 0.03 | 0.07 | Upgrade
|
| Asset Turnover | 0.38 | 0.38 | 0.42 | 0.46 | 0.52 | 0.51 | Upgrade
|
| Inventory Turnover | 0.87 | 0.87 | 0.77 | 1.33 | 3.69 | 1.87 | Upgrade
|
| Quick Ratio | 9.24 | 9.24 | 8.33 | 7.02 | 10.03 | 11.35 | Upgrade
|
| Current Ratio | 9.66 | 9.66 | 8.81 | 7.44 | 10.24 | 11.81 | Upgrade
|
| Return on Equity (ROE) | 16.30% | 16.30% | 19.39% | 21.09% | 18.62% | 28.95% | Upgrade
|
| Return on Assets (ROA) | 11.37% | 11.37% | 14.29% | 16.34% | 17.60% | 18.78% | Upgrade
|
| Return on Capital (ROIC) | 12.85% | 12.85% | 16.43% | 18.86% | 19.59% | 20.59% | Upgrade
|
| Return on Capital Employed (ROCE) | 18.70% | 18.70% | 23.60% | 26.20% | 27.30% | 28.60% | Upgrade
|
| Earnings Yield | 5.72% | 6.95% | 4.63% | 3.46% | 2.84% | 1.63% | Upgrade
|
| FCF Yield | 6.45% | 7.84% | 4.09% | 4.06% | 5.38% | 1.21% | Upgrade
|
| Dividend Yield | 0.42% | 0.49% | 0.34% | 0.28% | 0.27% | 0.08% | Upgrade
|
| Payout Ratio | 6.92% | 6.92% | 6.93% | 6.46% | 5.92% | 5.00% | Upgrade
|
| Buyback Yield / Dilution | 1.27% | 1.27% | 1.52% | -0.08% | -1.26% | -1.33% | Upgrade
|
| Total Shareholder Return | 1.69% | 1.75% | 1.86% | 0.21% | -0.99% | -1.25% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.